Molecular Profiling and Drug Testing in Children, Teenagers, and Young Adults with Acute Myeloid Leukemia at Diagnosis or Relapse

What this Trial Is About

Pediatric acute myeloid leukemias are serious diseases with a poor outlook and a high chance of relapse. This research aims to collect biological samples to study the genetic makeup of leukemic cells from children, teenagers, and young adults at diagnosis or relapse. The goal is to better understand the key genetic changes that cause resistance and may predict relapse risk. The study also explores bone marrow stem cells and tests how leukemic cells respond to multiple drugs outside the body. Participants include those under 25 years old with acute myeloid leukemia at first diagnosis or relapse, as well as patients with a genetic risk for leukemia or those undergoing bone marrow sampling without leukemia to serve as controls. Blood and bone marrow samples are collected, with multiple tubes taken at diagnosis and relapse for those with leukemia, and single samples for others. These samples are used for genetic sequencing, expression profiling, and drug testing. During the study, researchers will analyze the number of genetic mutations and other molecular features up to five years after sample collection. They will monitor relapse rates, survival without events, and disease-free survival. Other measurements include stem cell profiles, drug response patterns, and clearance of minimal residual disease. Participants may be followed for up to five years to assess these outcomes and better understand leukemia biology and treatment resistance.

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies